Tech Company Financing Transactions
Verdezyne Funding Round
On 4/29/2014, Verdezyne received $48 million in funding from Sime Darby Berhad, BP Ventures and DSM Venturing.
Transaction Overview
Company Name
Announced On
4/29/2014
Transaction Type
Venture Equity
Amount
$48,000,000
Round
Undisclosed
Investors
Sime Darby Berhad (Lead Investor) (Tan Salleh)
Proceeds Purpose
The funds will be used to accelerate Verdezyne's technology development in the U.S., and support various collaborative projects with Sime Darby's newly-formed business unit, Sime Darby Renewables.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2715 Loker Ave. West
Carlsbad, CA 92010
USA
Carlsbad, CA 92010
USA
Phone
Website
Email Address
Overview
Verdezyne employs its biology expertise and proprietary advanced computational algonithms to design and synthesize novel, high-diversity gene libraries for engineering proteins, metabolic pathways, and microorganisms.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
William Radany
Chief Financial Officer
Brian Conn
VP - Engineering
Bill Evanko
VP - General Counsel
Nancy Oleski
VP - R & D
Tom Beardslee
Browse more venture capital transactions:
Prev: 4/28/2014: SI-BONE venture capital transaction
Next: 4/29/2014: AxioMed venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to document every notable VC transaction. VC investment data records on this site come from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs